Amgen not looking for 20%+ royalties, they want to take Regeneron out!

[anonymous]

And send a message that they will not be F ed with. Amgen will go hard for complete injunction so they can take Regeneron out. Amgen is vindictive and wants all Regeneron employees out on the streets. Never mess with an I-banker.

 

[anonymous]

No royalty. That's out the window now. Amgen is going to get Praluent removed and will switch all patients. They want monopoly so they can price higher and get all the patients. A monopoly is 100% royalty plus without rebates for net to gross it's like 130% royalty that goes up each year because now they can increase the price. When a competitor gets on market (RNAi PCSK9s), they will have 100% share and better contracting game to counter and slow RNAi PCSK9s uptake.

 

[anonymous]

No royalty. That's out the window now. Amgen is going to get Praluent removed and will switch all patients. They want monopoly so they can price higher and get all the patients. A monopoly is 100% royalty plus without rebates for net to gross it's like 130% royalty that goes up each year because now they can increase the price. When a competitor gets on market (RNAi PCSK9s), they will have 100% share and better contracting game to counter and slow RNAi PCSK9s uptake.

I work for Regeneron and we are hoping for the injunction to be upheld selling these drugs is a nightmare. I will gladly take the 6 months severance and move on with a big smile.

 

[anonymous]

I work for Regeneron and we are hoping for the injunction to be upheld selling these drugs is a nightmare. I will gladly take the 6 months severance and move on with a big smile.

As a Repatha rep, that's probably smart. The outcomes data probably be mediocre but not outstanding. The price will still be high and access will be moderately improved. Amgen will expect us to sell this 10X with a complete monopoly. The reality is that slightly better access and no praluent means 3X sales. This will be well below Amgen's pipe dream forecast and we will all suffer as marketing will be off the hook with no competitors.

 

[anonymous]

layoffs will be delayed from 2017 to 2018-Repatha will not come close to hitting expectations

 

[anonymous]

You Guys are idiots. Just negotiate as this is a landmark case. Providers are already pissed at Amgen for this lawsuit. Lets just take our 25 % and go home and leave everyone with their jobs. Regeneron outcomes is looking better than ours. They had a sicker, higher acuity patient base in their clinical outcomes trials. We look like we just have sour grapes! Make the deal.

 

[anonymous]

You Guys are idiots. Just negotiate as this is a landmark case. Providers are already pissed at Amgen for this lawsuit. Lets just take our 25 % and go home and leave everyone with their jobs. Regeneron outcomes is looking better than ours. They had a sicker, higher acuity patient base in their clinical outcomes trials. We look like we just have sour grapes! Make the deal.

We have a greedy CEO who is a former investment banker. He will get every penny he can. He wants praluent off more to show his strength and for his ego.

 

[anonymous]

• Praluent won't likely get a stay during the appeal so product likely pulled in Q1
• Even after 18 month appeal, Praluent injunction likely to be upheld
• Amgen never settles IP cases and only 20% of cases like this ever go to royalties.

http://www.investors.com/news/techn...eneron-sanofi-in-amgen-patent-battle-leerink/

Biotech Amgen (AMGN) will likely triumph in a patent battle with Regeneron Pharmaceuticals (REGN) and Sanofi (SNY), requiring the duo to pull LDL-buster Praluent from the shelves — an unprecedented first, Leerink analyst Geoffrey Porges said Friday.

Regeneron and Sanofi have asked a federal circuit judge to grant a stay of the injunction beyond 45 days. That would allow them to market Praluent during the appeal, which typically runs up 16 months, Porges wrote in a research report Friday.

But the odds don't look good. Specialists believe "regardless of the ultimate merits of Regeneron and Sanofi's case, they will face an unprecedented (and probably first) branded pharmaceutical product withdrawal in the middle of this quarter," he wrote.

The most important catalyst will be whether the Federal Circuit extends the stay, Porges says. Of 158 permanent injunctions (PIs) granted in federal or district court since a 2006 case involving Ebay, only 37 parties (23%) were granted a stay.

In Regeneron and Sanofi's case, though, it would be the first time a branded drug would be pulled from shelves as a result of patent litigation. They have made the argument that public interest would not be served by pulling Praluent, which offers a lower dosage than Amgen's Repatha.

Examining medical-device cases, the district court has stayed a PI in five cases. But at the federal level, the PI was affirmed and not extended, resulting in the removal of those products from the market. Those precedents appear to be "stacked" against Regeneron and Sanofi, Porges said.

To Regeneron and Sanofi's public interest argument, Porges noted that public interest is actually better served in siding with the patent holder, thus encouraging the risky investment required in bringing an innovative product to market.

Porges also looks at several outcomes. It's possible that the case could be remanded to the district court. The federal circuit could also require Amgen, Regeneron and Sanofi to seek settlement assistance via the Circuit Mediation Office. But that process only happens in 10%-20% of cases.

Amgen, the No. 1 biotech firm by market cap, is unlikely to settle, he wrote. The company "notoriously takes the stance to never settle IP disputes and vigorously defends the company's IP, as evidenced by the blockage of market entry for Roche's Epogen competitor Mircera until the infringed patent expired."